Chronic blockade of CD28-B7-mediated T-cell costimulation by CTLA4IG reduces intimal thickening in MHC class I and II incompatible mouse heart allografts

Transplantation

Volumn 64, Issue 12, 1997, Pages 1641-1645

  Glysing Jensen, Troels ^a   Räisänen Sokolowski, Anne ^a   Sayegh, Mohamed H ^b   Russell, Mary E ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOSCLEROSIS; ARTERY INTIMA PROLIFERATION; BLOOD VESSEL OCCLUSION; CONFERENCE PAPER; CONTROLLED STUDY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION; ARTERIOSCLEROSIS; GRAFT SURVIVAL; HEART; HEART TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNITY, CELLULAR; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; TUNICA INTIMA;

EID: 0344765483     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199712270-00002     Document Type: Conference Paper

References (26)

1. Paul LC, Fellstrom B. Chronic vascular rejection of the heart and the kidney - have rational treatment options emerged? Transplantation 1992; 53(6): 1169.
2. Billingham ME. Chronic rejection in human allografts. In: Orosz CG, Sedmark DD, Ferguson RM, eds. Transplant Vascular Sclerosis. Austin, TX: R.G. Landes, 1995: 35.
3. Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995; 59(3): 313.
4. Colvin RB, Chase CM, Winn HJ, Russell PS. Chronic allograft arteriopathy: insight from experimental models. In: Orosz CG, Sedmark DD, Ferguson RM, eds. Transplant vascular sclerosis. Austin, TX: R.G. Landes, 1995: 7.
5. Cramer DV, Wu GD, Chapman FA, Cajulis E, Wang HK, Makowka L. Lymphocytic subsets and histopathologic changes associated with the development of heart transplant arteriosclerosis. J Heart Lung Transplant 1992; 11: 458.
6. Adams DH, Wyner LR, Karnovsky MJ. Experimental graft arteriosclerosis. II. Immunocytochemical analysis of lesion development. Transplantation 1993; 56(4): 794.
7. Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. I. Time course and immunogenetic and immunopathological considerations. Am J Pathol 1994; 144(2): 260.
8. Russell ME, Wallace AF, Hancock WW, et al. Upregulation of cytokines associated with macrophage activation in the Lewis to F344 rat chronic cardiac rejection model. Transplantation 1995; 59(4): 572.
9. Meiser BM, Billingham ME, Morris RE. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. Lancet 1991; 338(8778): 1297.
10. Gregory CR, Huie P, Billingham ME, Morris RE. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury: its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation 1993; 55(6): 1409.
11. Hirozane T, Matsumori A, Furukawa Y, Sasayama S. Experimental graft coronary artery disease in a murine heterotopic cardiac transplant model. Circulation 1995; 91: 386.
12. Russell P, Chase C, Colvin R. Coronary atherosclerosis in transplanted mouse hearts. IV. Effects of treatment with monoclonal antibodies to intercellular adhesion molecule-1 and leukocyte function-associated antigen-1. Transplantation 1995; 60: 724.
13. Shi C, Lee W-S, He Q, et al. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci USA 1996; 93: 4051.
14. Räisänen-Sokolowski A, Glysing-Jensen T, Mottram P, Russell M. Sustained anti-CD4/CD8 blocks inflammatory activation and intimai thickening in mouse heart allografts. Arterioscler Thromb Vasc Biol 1997; 17: 2115.
15. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89(22): 11102.
16. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561.
17. Boussiotis VA, Gribben JG, Freeman GJ, Nadler LM. Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance. Curr Opin Immunol 1994; 6(5): 797.
18. Sayegh MH, Turka LA. T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction. J Am Soc Nephrol 1995; 6: 1143.
19. Russell ME, Hancock WW, Akalin E, et al. Chronic cardiac rejection in the LEW to F344 rat model: blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest 1996; 97(3): 833.
20. Wallace PM, Johnson JS, MacMaster JF, Kennedy KA, Gladstone P, Linsley PS. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation 1994; 58(5): 602.
21. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice: the role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16(4): 343.
22. Lin H, Boiling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4 Ig plus donor-specific transfusion. J Exp Med 1993; 178(5): 1801.
23. Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP. Transplantation tolerance induced by CTLA4-Ig. Transplantation 1994; 57(12): 1701.
24. Mottram PL, Han WR, Purcell LJ, McKenzie IF, Hancock WW. Increased expression of IL-4 and IL-10 and decreased expression of IL-2 and interferon-gamma in long-surviving mouse heart allografts after brief CD4-monoclonal antibody therapy. Transplantation 1995; 59(4): 559.
25. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381(6581): 434.
26. Lakkis FG, Konieczny BT, Saleem S, et al. Blocking the CD28-B7 T cell costimulation pathway induces long term cardiac allograft acceptance in the absence of IL-4. J Immunol 1997; 158(5): 2443.